United Therapeutics (UTHR) Tops Q4 EPS Views
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Wall St slumps as sharp tech losses put Nasdaq on course for correction
- Massive market rotation raises question: Is the sell-AI trade here to stay?
- Goldman sees major AI and data center policy implications from ‘blue tsunami’
- Apple seeks to raise up to $7 billion in seven-tranche bond offering
- Nvidia chips stockpile in Hong Kong awaits China import approval - report
Tweet
Share
E-mailGet Alerts UTHR Hot Sheet
Price: $596.28 -2.01%
Financial Fact:
Diluted (in shares): 46.2M
Today's EPS Names:
KELYA, ROX, KEEL, More
Financial Fact:
Diluted (in shares): 46.2M
Today's EPS Names:
KELYA, ROX, KEEL, More
Join SI Premium – FREE
United Therapeutics (NASDAQ: UTHR) reported Q4 adjusted EPS of $3.21, $1.18 better than the analyst estimate of $2.03. Revenue for the quarter came in at $346.4 million versus the consensus estimate of $336.22 million.
For earnings history and earnings-related data on United Therapeutics (UTHR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Becton Dickinson (BDX) Tops Q4 EPS by 8c; Offers Guidance
- DXP Enterprises (DXPE) Misses Q3 EPS by 1c
- Hudson Pacific Properties (HPP) Misses Q3 EPS by 265c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
